Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini oral session - Sarcoma

1522MO - Hormonal contraception and pregnancy and risk of progression or relapse in desmoid-type fibromatosis (DF)


17 Sep 2021


Mini oral session - Sarcoma


Cancer and Pregnancy;  Rare Cancers

Tumour Site





Annals of Oncology (2021) 32 (suppl_5): S1111-S1128. 10.1016/annonc/annonc712


M. DEBAUDRINGHIEN1, J. Blay2, A.M. BIMBAI3, S. Bonvalot4, A. Italiano5, C. Rousset-Jablonski6, N. Corradini7, S. Piperno-Neumann8, C.M. Chevreau9, J.E. Kurtz10, C. Guillemet11, E. Bompas12, O. Collard13, S. Salas14, A. Le Cesne15, D. Orbach16, J. Thery17, M. Le Deley18, O. Mir19, N. Penel20

Author affiliations

  • 1 Medical Oncology, Lille University, 59000 - Lille/FR
  • 2 Medicine Department, Centre Léon Bérard, 69008 - Lyon/FR
  • 3 Clinical Research, Centre Oscar Lambret, Lille/FR
  • 4 Dept. Surgery, Institut Curie, 75005 - Paris/FR
  • 5 Early Phase Trials Unit, Institute Bergonié, 33076 - Bordeaux/FR
  • 6 Medical Oncology, Centre Léon Bérard, Lyon/PF
  • 7 Pediatry, IHOPe - Institut d'Hématologie et d'Oncologie Pédiatrique, 69008 - Lyon/FR
  • 8 Medecine, Institut Curie, 75674 - PARIS/FR
  • 9 Oncology Department, Institut Universitaire du Cancer -Toulouse- Oncopole, 31059 - Toulouse/FR
  • 10 Medical Oncology Department, CHU Hautepierre, 67200 - Strasbourg/FR
  • 11 Medical Oncology, Centre Henri Becquerel, 76038 - Rouen/FR
  • 12 Oncology, ICO Institut de Cancerologie de l'Ouest René Gauducheau, 44805 - Saint-Herblain/FR
  • 13 Medecine, Institut de Cancérologie Lucien Neuwirth, 42270 - St-Priest-en-Jarez/FR
  • 14 Oncology, Ap-hm, 13005 - Marseille/FR
  • 15 Medical Oncology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 16 Pediatry, Institut Curie, 75005 - Paris/FR
  • 17 Clinical Research, Centre Oscar Lambret, 59000 - Lille/FR
  • 18 Methodology And Biostatistics, Centre Oscar Lambret, 59000 - Lille/FR
  • 19 Cancer Medicine Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 20 Medical Oncology, Centre Oscar lambret, 59000 - Lilles/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1522MO


DF is a locally aggressive tumor with unpredictable course, but most relapses/progressions occur within 2 years. Some indirect arguments suggest that DF could be a hormone-dependent tumor, and that recent exposure to hormonal contraception or pregnancy could influence DF outcome.


ALTITUDES (NCT02867033) is a nationwide cohort of incident DF, diagnosed from January 2016 to February 2021 and confirmed by central pathological review (Penel, ASCO 2021). In the present study, we have selected women with childbearing age. The primary endpoint was event-free survival EFS (including progression during active surveillance -AS -or relapse after surgery -SUR-). We estimated EFS Kaplan-Meier curves, and modeled the risk in Cox models. We considered hormonal contraception or pregnancy within the 2 years before DF.


We included 242 pts with a median age of 34.1 (range, 17.3-45.8). Abdominal wall is the most common tumor site (N=124, 51.5%). Pts were managed by AS (N=194) or SUR (N=48). Pregnancy occurred within 2 years before DF diagnosis, at the time of DF diagnosis and after DF diagnosis in 87 (36.0%), 12 (5.0%) and 24 cases (9.9%), respectively. Exposure to hormonal contraception within 2 years before diagnosis, at the time of diagnosis and after diagnosis concerned 107 (44.2%), 82 (33.9%) and 94 cases (38.8%). The median follow-up was 23.9 mo. (range, 0.4 to 59.7 mo.). The 2-year EFS rate was 74.5% (95%CI, 67.5-80.3%). We did not observe any association between pregnancy occurring within 2 years and EFS: 2-year EFS= 70.4% versus 76.9%, Hazard ratio=1.32 (0.77-2.28), p=0.31. We did not observe any association between exposure to hormonal contraception within 2 years and EFS: 2-year EFS= 78.5% versus 72.5%, Hazard ratio=0.84 (0.48-1.46), p=0.53. Results were stable in multivariate analysis. Subgroup analyses showed that effect of both pregnancy and hormonal contraception did not significantly differ according to primary site (abdominal wall versus other), age, tumor size and 1st-line strategy (AS versus SUR) (all interaction tests, p>0.15).


Pregnancy and exposure to hormonal contraception within 24 months did not influence DF outcome.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

Centre Oscar Lambret.


Ligue Nationale contre le Cancer, Fondation Institut Curie, InterSarc.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.